ライフサイエンスコーパス: tartrate

1 lution of YiaK alone and in complex with NAD-tartrate.

2 d in AMTPS formed by Triton X-114 and sodium tartrate.

3 anic host selectivity to preferentially bind tartrate.

4 ic charges and can be mimicked by suramin or tartrate.

5 ith higher specificity and potency than L(+)-tartrate.

6 presence of the competitive inhibitor, meso-tartrate.

7 rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [3

8 rats trained to discriminate saline from LSD tartrate (0.08 mg/kg).

9 rats trained to discriminate saline from LSD tartrate (0.08 mg/kg).

10 hosphonate (2.1 A), and a buffer additive, l-tartrate (1.7 A).

11 human donors received control or brimonidine tartrate (45 nM) for 1, 3, or 7 days.

12 two steps from dimethyl 2,3-O-benzylidene-d-tartrate (7).

13 attempted with a moderate dose of metoprolol tartrate, a beta-1-blocker that results in lesser clinic

14 s, we investigated the effect of varenicline tartrate, a relatively specific alpha4beta2 partial agon

15 s endogenously to the proximal region of the tartrate acid phosphatase (TRAP) gene promoter and suppr

16 meso-Tartrate also binds with a large DeltaC(p) value and lik

17 Ammonium tartrate also increased, then decreased the binding of 5

18 Although the binding of meso-tartrate also requires enzyme-bound K(+) and Mn(2+), the

19 Given the actions of varenicline tartrate and bupropion hydrochloride sustained-release (

20 changes in phenylalanine, dehydroascorbate, tartrate and formate were consistent with a higher deman

21 structures of active LasA as a complex with tartrate and in the uncomplexed form.

22 Metoprolol tartrate and MS produce similar hemodynamic and clinical

23 e-bound K(+) and Mn(2+), the binding of meso-tartrate and NAD is random.

24 Enzyme kinetics studies confirm that tartrate and the related D-malate are inhibitors of YiaK

25 omplexes with chiral ((R)/(S)-BINOL, diethyl tartrate) and achiral (piperazine and trigol) linkers wi

26 H,3H)-quinazoli nedione tartrate (ketanserin tartrate), and the non-selective 5-HT receptor agents, 2

27 rsenite, sodium arsenate, antimony potassium tartrate, and cadmium chloride.

28 (N-hydroxysuccinimide ester), disuccinimidyl tartrate, and dithiobis(succinimidyl) propionate, develo

29 ne-tartrate, d-dimethyl-2,3-O-isopropylidene-tartrate, and meso-erythritol, respectively.

30 caris suum will utilize L-aspartate, (2S,3R)-tartrate, and meso-tartrate as substrates with V/K value

31 dose of 25 mg carvedilol, 100 mg metoprolol tartrate, and placebo).

32 a C2-symmetric starting material, diethyl D-tartrate, and took advantage of a relay of diastereosele

33 Corey stien reagent, the Roush allylboronate tartrates, and the secondary amine Diels-Alder catalysts

34 s where ascorbic acid and antimony potassium tartrate are added and serve as reducing agents.

35 In this study, we have identified ammonium tartrate as a MS-compatible salt for HIC with comparable

36 ternary complex of the enzyme with NADP+ and tartrate as an inhibitor.

37 use of ascorbic acid and antimony potassium tartrate as reducing agents (as used in the colorimetric

38 lize L-aspartate, (2S,3R)-tartrate, and meso-tartrate as substrates with V/K values 10(-4)-10(-5) wit

39 ared carvedilol with short-acting metoprolol tartrate at different dose equivalents.

40 ), suggesting that K(+) is required for meso-tartrate binding.

41 dideoxyguanosine-5'-triphosphate, MnCl2, and tartrate, but their quaternary structure did not conform

42 dized by addition of dioxygen and a titanium tartrate catalyst to give epoxy alcohols with excellent

43 Our measurements indicate that tartrate, citrate, chloride, and nitrate anions are amon

44 ic method based on formation of the vanadate-tartrate complex.

45 Differences in Cu(2)(+)-tartrate complexes particle size and concentration were

46 Further increasing ammonium tartrate concentrations (500-2500 microM) decreased [3H]

47 apraclonidine hydrochloride, and brimonidine tartrate constitute the three topical alpha agonists tha

48 Ever since Pasteur noticed that tartrate crystals exist in two non-superimposable forms

49 hesized from l-dimethyl-2,3-O-isopropylidene-tartrate, d-dimethyl-2,3-O-isopropylidene-tartrate, and

50 on at least three different substrates (L(+)-tartrate, D-malate, and 3-isopropylmalate).

51 exposed to nicotine (6 mg kg(-1) of nicotine tartrate daily) or saline with an osmotic mini-pump impl

52 -1)) are consistent with assignment of the d-tartrate dehydratase (TarD) function.

53 late racemase, l-fuconate dehydratase, and d-tartrate dehydratase, the active site of TalrD/GalrD con

54 tes and inhibitors to different complexes of tartrate dehydrogenase (TDH) from Pseudomonas putida was

55 Tartrate dehydrogenase catalyzes the divalent metal ion-

56 ive decarboxylation of D-malate catalyzed by tartrate dehydrogenase has been analyzed by transient-st

57 drogenase, homoisocitrate dehydrogenase, and tartrate dehydrogenase, which have an (R)-hydroxyacid su

58 ration of the genome from the E protein in a tartrate density gradient.

59 In this study, a commercially available tartrate derivative was elaborated through a key late-st

60 allylboronates bearing the readily available tartrate derivative were obtained via sigmatropic rearra

61 Conversion of the adduct to a mixture of tartrate-derived ketals followed by separation of the di

62 10-15-membered rings was achieved by using a tartrate-derived linker to attach ene and yne subunits.

63 MeOH/H(2)O, revealed that the antimony(III)-tartrate dianion associates to solvent reaction products

64 In contrast, meso-tartrate does bind to E/K(+)/Mn(2+) but gives no signifi

65 e administered nicotine bitartrate or sodium tartrate either during adolescence (p29-43) or adulthood

66 r was not significantly enhanced by ammonium tartrate (Emax approximately 13%).

67 as well as thioether 8 were synthesized from tartrates employing Ley's "BDA" and "Dispoke" methodolog

68 s for the allylboration reaction between the tartrate ester and tartramide modified allylboronates an

69 ealed that the predominant species in Ti/PEG tartrate ester mixtures is a distinct 2:1 Ti-ligand comp

70 ic reaction of N-acetyl-d-alaninal 1 and the tartrate ester modified (E)-crotylboronate (R,R)-2.

71 s into the recently disputed report that PEG tartrate esters can reverse the enantioselectivity of th

72 e investigated by administering (-)-nicotine tartrate for 5 days either continuously in doses of 5.01

73 In the phase 3 Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease

74 gential flow filtration (TFF-DB) or glycerol tartrate gradient sedimentation (GT-DB) constitute 92% o

75 articles sedimented abnormally in a glycerol-tartrate gradient, indicating that the structure of the

76 more, GABA increased the potency of ammonium tartrate in enhancing [3H]flunitrazepam binding by 63%.

77 ctrometry (ESI-MS) analysis of antimony(III)-tartrate in frequently used solvent systems, ACN/H(2)O a

78 he superiority of carvedilol over metoprolol tartrate in one clinical trial is demonstrated, and mult

79 nalysis unexpectedly revealed the binding of tartrate in the active site.

80 that the selectivity obtained with ammonium tartrate in the HIC mobile phases is orthogonal to that

81 An abiotic formation of meso- and DL-tartrates in 80% yield via the cyanide-catalyzed dimeriz

82 de, sodium arsenite, and potassium antimonyl tartrate (in order of effectiveness), the same inducers

83 and crystal structures of 11 alkaline earth tartrates, including an unusual I(3)O(0) framework, [Ba(

84 The ammonium tartrate-induced alterations in [3H]muscimol binding wer

85 The ammonium tartrate-induced increase in [3H]flunitrazepam binding w

86 tase binary complex erroneously positioned D-tartrate into the active site.

87 n an achiral gold surface in the presence of tartrate ion in the deposition solution, the chirality o

88 of 46 acid sugars and discovered that only d-tartrate is dehydrated, yielding oxaloacetate as product

89 e Mitsunobu reaction in which catalytic zinc tartrate is used to enhance the nucleophilicity of the t

90 perdinyl]ethyl]-2,4(1H,3H)-quinazoli nedione tartrate (ketanserin tartrate), and the non-selective 5-

91 By preparing a range of tartrate ligands with varying PEG chains lengths, the re

92 nicotine replacement therapy and varenicline tartrate may aid cessation treatment.

93 ues of about 6.3 and 8.3, while that for V/K(tartrate) (measured from pH 7.5 to pH 9) exhibits a pK(a

94 A tartrate-mediated nucleophilic epoxidation involving hyd

95 imilarity to a product of ttuD essential for tartrate metabolism in Agrobacterium vitis.

96 n, we monitor the crystallization of lithium tartrate MOFs, observing the successive crystallization

97 Metoprolol tartrate (MPT) concentration (10 and 40% in Eudragit RSP

98 n = 498) or 50- to 200-mg dose of metoprolol tartrate (n = 737), each twice daily.

99 Meso-tartrate occupies a position close to that of the bound

100 y subjects was treated with 0.2% brimonidine tartrate ophthalmic solution to induce pupil size reduct

101 the acid phosphatase inhibitors citrate and tartrate or the protein serine/threonine phosphatase inh

102 The ligands Mn(2+), meso-tartrate, oxalate, and reduced nicotinamide adenine dinu

103 emotherapy with trivalent potassium antimony tartrate (PAT) and, more importantly, pentavalent antimo

104 t to killing by the drug potassium antimonyl tartrate (PAT).

105 Calcium forms unique l-, meso-, and d,l-tartrate phases which persist to 220 degrees C.

106 e small orally, available molecule, Posiphen tartrate (Posiphen), lowers secreted (s) amyloid-beta pr

107 gamma-aminobutyric acid A receptor, zolpidem tartrate presents a potential treatment mechanism for ot

108 y, coupled with the remarkable efficiency of tartrate production from glyoxylate, merits consideratio

109 ous crystallographic studies compiled on the tartrate-rat prostatic acid phosphatase binary complex e

110 sually separated into tartrate-resistant and tartrate-refractory, which is reported as the prostatic

111 sphatase-positive osteoblasts and diminished tartrate resistance acid phosphatase-positive osteoclast

112 Meanwhile, CLA significantly reduced femur tartrate resistant acid phosphatase (TRAP) activity, sug

113 Hemin inhibits transcription of the tartrate resistant acid phosphatase (TRAP) gene.

114 en c-src proto-oncogene from the promoter of tartrate resistant acid phosphatase (TRAP), a gene that

115 stal side of the molars until 6 months using tartrate resistant acid phosphatase (TRAP).

116 The enzyme tartrate resistant acid phosphatase (TRAP, two isoforms

117 nduce osteoclast formation was determined by tartrate resistant acid phosphatase assay.

118 of nuclear factor-kappaB ligand (RANKL) and tartrate resistant acid phosphatase were significantly d

119 iding cells expressing the osteoclast marker tartrate resistant acid phosphatase, in vivo.

120 A parallel series of tartrate resistant acid phosphatase-stained sections wer

121 The isolated approximately 28-kDa enzyme was tartrate resistant and displayed narrow substrate specif

122 id phosphatase activity that, unlike Map, is tartrate resistant.

123 urface membrane phospho-monoesterase, i.e. a tartrate-resistant acid phosphatase (Cl MAcP) was also f

124 However, the absence of tartrate-resistant acid phosphatase (TRAP) activity and

125 ic differentiation as evidenced by increased tartrate-resistant acid phosphatase (TRAP) activity and

126 the number of multinuclear cells expressing tartrate-resistant acid phosphatase (TRAP) activity prod

127 The inhibition of osteoclastogenesis and tartrate-resistant acid phosphatase (TRAP) activity was

128 ounterparts they are larger, fail to express tartrate-resistant acid phosphatase (TRAP) activity, and

129 e colocalization of messenger RNA (mRNA) for tartrate-resistant acid phosphatase (TRAP) and cathepsin

130 toplasmic, calcineurin-dependent 1 (NFATc1), tartrate-resistant acid phosphatase (TRAP) and cathepsin

131 ere performed on media and cell lysates, and tartrate-resistant acid phosphatase (TRAP) and mRNA dete

132 Serial sections were reacted for tartrate-resistant acid phosphatase (TRAP) and nonspecif

133 -dihydroxycholecalciferol and coincided with tartrate-resistant acid phosphatase (TRAP) expression, a

134 d alkaline phosphatase (AP) for osteoblasts; tartrate-resistant acid phosphatase (TRAP) for osteoclas

135 ast differentiation, plays a pivotal role in tartrate-resistant acid phosphatase (TRAP) gene expressi

136 a novel CD gene regulated by the osteoclast tartrate-resistant acid phosphatase (TRAP) gene promoter

137 e sialoprotein (BSP), osteocalcin (OCN), and tartrate-resistant acid phosphatase (TRAP) immunohistoch

138 IL-4 down-regulates expression of tartrate-resistant acid phosphatase (TRAP) in mature ost

139 ecessary for activation of target genes like tartrate-resistant acid phosphatase (TRAP) in osteoclast

140 Tartrate-resistant acid phosphatase (TRAP) is an iron-co

141 The tartrate-resistant acid phosphatase (TRAP) is present in

142 d hematoxylin and eosin and subjected to the tartrate-resistant acid phosphatase (TRAP) method.

143 These MNCs were also positive for tartrate-resistant acid phosphatase (TRAP) mRNA and TRAP

144 Tartrate-resistant acid phosphatase (TRAP) plays an impo

145 Tartrate-resistant acid phosphatase (TRAP) staining show

146 was analyzed by immunohistochemistry, using tartrate-resistant acid phosphatase (TRAP) staining to i

147 Tartrate-resistant acid phosphatase (TRAP) staining, res

148 nalysis and immunohistochemical detection of tartrate-resistant acid phosphatase (TRAP) were also per

149 B ligand (RANKL), osteoprotegerin (OPG), and tartrate-resistant acid phosphatase (TRAP) were assessed

150 Histological sections stained for tartrate-resistant acid phosphatase (TRAP) were quantifi

151 a strongly reduced formation of multinuclear tartrate-resistant acid phosphatase (TRAP)(+) osteoclast

152 appaB ligand (RANKL), osteoprotegerin (OPG), tartrate-resistant acid phosphatase (TRAP), and activate

153 eptor activator of NK-kappaB ligand (RANKL), tartrate-resistant acid phosphatase (TRAP), and osteocla

154 ocollagen I carboxy-terminal propeptide, and tartrate-resistant acid phosphatase (TRAP), and urinary

155 on of matrix metallopeptidase 13 (MMP13) and tartrate-resistant acid phosphatase (TRAP), leading to a

156 Cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP), Oregon Green

157 BL, TBA, the positive cells for tartrate-resistant acid phosphatase (TRAP), receptor act

158 significant elevation of the active form of tartrate-resistant acid phosphatase (TRAP)-5b.

159 sence of IL-4, we detected the appearance of tartrate-resistant acid phosphatase (TRAP)-negative mult

160 st/periodontal ligament cells displayed more tartrate-resistant acid phosphatase (TRAP)-positive cell

161 nificantly lower level of bone loss and less tartrate-resistant acid phosphatase (TRAP)-positive cell

162 igature-induced bone loss in mice with fewer tartrate-resistant acid phosphatase (TRAP)-positive cell

163 counted as bone-associated multi-nucleated, tartrate-resistant acid phosphatase (TRAP)-positive cell

164 confirmed the decreased bone mass, increased tartrate-resistant acid phosphatase (TRAP)-positive cell

165 NF-kappaB ligand formation of multinucleated tartrate-resistant acid phosphatase (TRAP)-positive cell

166 Tartrate-resistant acid phosphatase (TRAP)-positive oste

167 matoxylin and eosin, immunohistochemical, or tartrate-resistant acid phosphatase (TRAP)-stained secti

168 ltinucleated cells that stained positive for tartrate-resistant acid phosphatase (TRAP).

169 B ligand (RANKL), osteoprotegerin (OPG), and tartrate-resistant acid phosphatase (TRAP).

170 otegerin expression, and a decrease in serum tartrate-resistant acid phosphatase (TRAP5b) concentrati

171 Tartrate-resistant acid phosphatase (type V) (TRAP) was

172 -cells, c1 (NFATc1), cathepsin K (Cstk), and tartrate-resistant acid phosphatase 5 (TRAP) with recept

173 unting of the in vivo bone resorption marker tartrate-resistant acid phosphatase 5b (TRACP 5b).

174 serum bone alkaline phosphatase (B-ALP) and tartrate-resistant acid phosphatase 5b (TRAP-5b), and ca

175 this was accompanied by an increase in serum Tartrate-resistant acid phosphatase 5b (TRAP5b) levels.

176 Even though tartrate-resistant acid phosphatase 5b was expressed, pr

177 rocollagen type-1 N-terminal propeptide, and tartrate-resistant acid phosphatase 5b were associated w

178 elopeptide of type I collagen) and TRACP-5b (tartrate-resistant acid phosphatase 5b).

179 procollagen type-1 N-terminal propeptide, or tartrate-resistant acid phosphatase 5b; these values cor

180 ophospholipase A, and tartrate-sensitive and tartrate-resistant acid phosphatase activities and influ

181 d by analyses for calcium release or uptake, tartrate-resistant acid phosphatase activity (marker for

182 eveal a previously unrecognized link between tartrate-resistant acid phosphatase activity and interfe

183 nto osteoclasts was assessed by staining for tartrate-resistant acid phosphatase activity.

184 factor I concentrations and increased serum tartrate-resistant acid phosphatase and 25-hydroxyvitami

185 ive induction of OCL-specific genes, such as tartrate-resistant acid phosphatase and immunoreceptor O

186 Tartrate-resistant acid phosphatase and osteocalcin were

187 e, multinucleated osteoclasts that expressed tartrate-resistant acid phosphatase and were capable of

188 sed by enzyme-linked immunosorbent assay and tartrate-resistant acid phosphatase assay.

189 enerated with a transgenic construct using a tartrate-resistant acid phosphatase exon 1C promoter to

190 could collaborate with MITF to activate the tartrate-resistant acid phosphatase gene promoter depend

191 lammation were assessed by histomorphometry, tartrate-resistant acid phosphatase histoenzymology, and

192 eptor type 4, nuclear factor kappa beta, and tartrate-resistant acid phosphatase immunostaining.

193 Osteoclast morphology was analyzed in tartrate-resistant acid phosphatase or F-actin-stained s

194 proximately 5% of the mononuclear cells were tartrate-resistant acid phosphatase positive, and these

195 specimens contained MNCs that were intensely tartrate-resistant acid phosphatase positive; approximat

196 We used the tartrate-resistant acid phosphatase promoter to target t

197 Tartrate-resistant acid phosphatase reaction and immunoh

198 and function were assessed via quantitative tartrate-resistant acid phosphatase staining and degrada

199 Tartrate-resistant acid phosphatase staining demonstrate

200 Mmp-2, and Mmp-14 were expressed widely, and tartrate-resistant acid phosphatase staining notably was

201 ysis, microcomputed tomography analysis, and tartrate-resistant acid phosphatase staining revealed re

202 Tartrate-resistant acid phosphatase staining was used to

203 leated giant cells with varying intensity of tartrate-resistant acid phosphatase staining were regula

204 H&E and tartrate-resistant acid phosphatase staining were used t

205 human preosteoclastic cells was assessed by tartrate-resistant acid phosphatase staining, whereas th

206 al fluid (SF) macrophages were determined by tartrate-resistant acid phosphatase staining.

207 hemistry, and osteoclasts were enumerated by tartrate-resistant acid phosphatase staining.

208 ated osteoclastic cells was determined after tartrate-resistant acid phosphatase staining.

209 PBMC differentiation to OCs was confirmed by tartrate-resistant acid phosphatase staining; bone resor

210 mouse tails, using hematoxylin and eosin and tartrate-resistant acid phosphatase to confirm the prese

211 received Scl-AbI, although levels of type 5b tartrate-resistant acid phosphatase were significantly l

212 TRAP (tartrate-resistant acid phosphatase)-positive osteoclast

213 xpress the purple, band 5 isozyme (Acp 5) of tartrate-resistant acid phosphatase, a binuclear metallo

214 ing matrix metalloproteinase 9, cathepsin K, tartrate-resistant acid phosphatase, and carbonic anhydr

215 ure, downregulation of the HCL markers CD25, tartrate-resistant acid phosphatase, and cyclin D1, smoo

216 OCs, including multinucleation, presence of tartrate-resistant acid phosphatase, and expression of t

217 m the center of the lesion, were stained for tartrate-resistant acid phosphatase, and histomorphometr

218 ls, expression of receptors for AGEs (RAGE), tartrate-resistant acid phosphatase, and proliferating c

219 expression of the receptor for AGEs (RAGE), tartrate-resistant acid phosphatase, and proliferating c

220 line phosphatase, bone alkaline phosphatase, tartrate-resistant acid phosphatase, and urinary cross-l

221 ophathalmia-associated transcription factor, tartrate-resistant acid phosphatase, cathepsin K, and be

222 gulate calcitonin receptor, but they express tartrate-resistant acid phosphatase, cathepsin K, and be

223 Sequencing of ACP5, encoding tartrate-resistant acid phosphatase, identified bialleli

224 crophage marker CD11b, the osteoclast marker tartrate-resistant acid phosphatase, or carbonic anhydra

225 Serum levels of human OPG-Fc and tartrate-resistant acid phosphatase-5b (TRAP-5b) were me

226 ssenger RNA and protein, along with elevated tartrate-resistant acid phosphatase-positive (TRAP+) OCs

227 ha tumors associated with significantly more tartrate-resistant acid phosphatase-positive (TRAP+) ost

228 ns, serum interleukin (IL)-1beta levels, and tartrate-resistant acid phosphatase-positive (TRAP+) ost

229 y features of the osteoclast: multinucleated tartrate-resistant acid phosphatase-positive cell format

230 lasts as the number of pits produced by each tartrate-resistant acid phosphatase-positive cell is red

231 Mice with depletion of PDGF-BB in the tartrate-resistant acid phosphatase-positive cell lineag

232 The number of multinucleated tartrate-resistant acid phosphatase-positive cells along

233 wer maturation into osteoclasts with reduced tartrate-resistant acid phosphatase-positive cells and d

234 These multinucleated, tartrate-resistant acid phosphatase-positive cells were

235 ion and maintenance of large multinucleated, tartrate-resistant acid phosphatase-positive cells.

236 No tartrate-resistant acid phosphatase-positive multinuclea

237 ion were evaluated by counting the number of tartrate-resistant acid phosphatase-positive multinuclea

238 x metalloproteinase 9, and the generation of tartrate-resistant acid phosphatase-positive multinuclea

239 cent to and distal from pannus invasion, and tartrate-resistant acid phosphatase-positive multinuclea

240 (C453S) significantly enhanced the number of tartrate-resistant acid phosphatase-positive multinuclea

241 GM1 with primary bone marrow cells generated tartrate-resistant acid phosphatase-positive multinuclea

242 teoclast cell fusion, forming multinucleated tartrate-resistant acid phosphatase-positive osteoclast-

243 egenerative cell lines reduced the number of tartrate-resistant acid phosphatase-positive osteoclast-

244 ysis was characterized by reduced numbers of tartrate-resistant acid phosphatase-positive osteoclasts

245 Catabolic activity was analyzed with tartrate-resistant acid phosphatase-positive osteoclasts

246 ells in vitro, as evidenced by a decrease in tartrate-resistant acid phosphatase-positive osteoclasts

247 yelomonocytic precursors into multinucleated tartrate-resistant acid phosphatase-positive osteoclasts

248 The number of tartrate-resistant acid phosphatase-positive osteoclasts

249 or induction of bone marrow macrophages into tartrate-resistant acid phosphatase-positive preosteocla

250 -29b, or -29c diminished formation of TRAP (tartrate-resistant acid phosphatase-positive) multinucle

251 Osteoclasts were counted in tartrate-resistant acid phosphatase-stained sections.

252 ors including NFAT2, TRAF6, cathepsin K, and tartrate-resistant acid phosphatase.

253 lcin, bone-specific alkaline phosphatase, or tartrate-resistant acid phosphatase.

254 ) were stained with hematoxylin and eosin or tartrate-resistant acid phosphatase.

255 sections stained with hematoxylin-eosin and tartrate-resistant acid phosphatase.

256 orrelated with expression of the target gene tartrate-resistant acid phosphatase.

257 ent decrease in secretion of cathepsin B and tartrate-resistant acid phosphatase.

258 The number of osteoclasts was determined by tartrate-resistant acid phosphatase.

259 xacin; V-ATPase, vacuolar H(+)-ATPase; TRAP, tartrate-resistant acid phosphatase; alphaMEM D10, minim

260 eated with aPDT exhibited reduced numbers of tartrate-resistant acid-phosphatase-positive cells and m

261 es based on the number of multinucleated and tartrate-resistant alkaline phosphatase-positive cells a

262 inhibiting Acps, F. tularensis Acp (AcpA) is tartrate-resistant and has broad substrate specificity.

263 in the blood serum is usually separated into tartrate-resistant and tartrate-refractory, which is rep

264 vely expresses a unique externally oriented, tartrate-resistant, acid phosphatase on its surface memb

265 ssect the functional domains of this unique, tartrate-resistant, surface membrane enzyme.

266 l)-tropane-2beta-carboxylic acid methylester tartrate (RTI-55) whole-cell binding is increased by NEC

267 2-ylmethyl)-2-hydroxy-6-methoxybenzamide (+)-tartrate salt (raclopride; 0, 0.2, or 0.4 mg/kg) on the

268 ations involve resolution-crystallization of tartrate salt 6 followed by a one-pot procedure for the

269 that Map, like its eukaryotic homologs, is a tartrate-sensitive acid phosphatase.

270 A, phospholipase C, lysophospholipase A, and tartrate-sensitive and tartrate-resistant acid phosphata

271 ells were defined by increased expression of tartrate-sensitive prostatic acid phosphatase as a broad

272 itol) and its enantiomer (derived from l-(+)-tartrate) serve as key starting materials, which are ela

273 ed wine, they had been cross-validated in Zn-tartrate solutions.

274 In clone 33 LNCaP cells, L-(+)-tartrate suppresses the cellular PAcP activity and cause

275 ce daily) and 1518 to metoprolol (metoprolol tartrate, target dose 50 mg twice daily).

276 introduced ligands are malonate, succinate, tartrate, tartronate, pyruvate, and glyoxalate.

277 is an order of magnitude more selective for tartrate than malate.

278 periments of Rochelle salt (sodium potassium tartrate), the protein lysozyme, and has been employed f

279 e has higher selectivity for citrate over DL-tartrate, the formation of the aptamer:receptor complex

280 more closed conformation, the binding of NAD-tartrate to YiaK produces a more open active site.

281 zes the metal ion-dependent oxidation of (+)-tartrate to yield oxaloglycolate and NADH.

282 Simple dehydration of tartrates to oxaloacetate and an ensuing decarboxylation

283 ate kinase and that the serine cycle and the tartrate utilization pathway share a series of reactions

284 The commonly used sedative zolpidem tartrate was implicated in 11.5% (95% CI, 9.5%-13.4%) of

285 omplexed with the competitive inhibitor l(+)-tartrate was solved using single-wavelength anomalous di

286 eridinyl]ethyl]-2,4(1H,3H)-quinazolinedion e tartrate) was ineffective.

287 nding of the bis(alpha-hydroxycarbolxylate), tartrate, was assessed and compared to the corresponding

288 3 hydroxyl group on the D(-)-stereoisomer of tartrate, which does not significantly inhibit prostatic

289 by ammonium (10-500 microM), but not sodium tartrate with EC50 = 98 microM and Emax = 31%.

290 the effectiveness of intravenous vinorelbine tartrate with intravenous fluorouracil and leucovorin (5

291 is degraded via L-idonate to L-threarate (L-tartrate), with the latter arising from carbons 1-4 of a